MedWatch

Biotech firm funded for rapid vaccine development with Covid-19 as first target

Through the use of a new technology, Evaxion Biotech is banking on developing vaccines against future pandemics in only 13 weeks time.  A vaccine against Covid-19 could be the first in line, and the economic potential of the technology is enormous, says CBO/CMO.

Niels Iversen Møller,Evaxion's founder and CBO/CMO. | Foto: Evaxion Biotech / PR

Copehagen-based biotech firm Evaxion Biotech, founded in 2008, and which since has worked to develop the customized cancer treatment of the future, is now entering the market for the development of vaccines against pandemics such as the ongoing Covid-19.

With DKK 4.8 million (USD 758.8 million) in aid from Innovation Fund Denmark, the company is now getting started with the development of its Raven platform, which aims to develop vaccines against future pandemics in real time as such occur.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Biontech-direktører: Derfor måtte Afrika vente på coronavacciner

Tyske Biontech vil bruge de mange corona-milliarder på at hjælpe lande i Afrika med at komme både coronavirus, malaria og turberkulose til livs, men alligevel stod kontinentet langt nede i køen, da de første coronavacciner skulle distribueres. MedWatch har spurgt hvorfor.

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier